Market Overview:
The global testicular cancer drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of testicular cancer, rising awareness about early diagnosis and treatment options for testicular cancer, and technological advancements in the field of oncology. Based on type, the global testicular cancer drugs market is segmented into cisplatin, etoposide, ifosfamide, paclitaxel, vinblastine, bleomycin and dactinomycin. Based on application, the market is segmented into seminomas (pure germ cell tumors), non-seminomas (mixed tumors that contain both seminoma and non-seminoma cells), leydig cell cancer (cancer that arises from cells within the Leydig cells of the testes that produce testosterone), sertoli cell cancer (cancer that arises from Sertoli cells – which are located in between germ cells and support them by secreting hormones) and other applications. Geographically speaking; North America dominates this market followed by Europe due to better reimbursement scenario for advanced therapies coupled with rising incidence rates of various types of cancers including testicular cancers in these regions.
Product Definition:
Testicular cancer drugs are used to treat a type of cancer that begins in the testicles. The most common type of testicular cancer is called seminoma. There are different types of treatments for testicular cancer, including surgery, radiation therapy, and chemotherapy.
Cisplatin:
Cisplatin is a platinum-based chemotherapy drug used in the treatment of various cancers such as ovarian, cervical, lung and breast cancer. Cisplatin has been found to be more effective than carboplatin in treating advanced ovarian cancer. It is also used along with other chemotherapeutic drugs for the treatment of testicular cancer (testicular carcinoma).
Etoposide:
Etoposide, also known as Etopophos, is an immunomodulating drug that interferes with the cell division cycle and is used in the treatment of testicular cancer. It was first synthesized by a group of researchers at Merck & Co., Inc. in 1970 for treatment of bladder cancer but it failed during clinical trials.
Application Insights:
The non-seminomas segment held the largest share of the global market in 2017. This is due to a high prevalence of testicular cancer in developing countries, such as India and China. According to data published by WHO, around 60% of patients diagnosed with testicular cancer are diagnosed in developing countries. The same study also states that around 1 out of 5 men between 15 and 35 years have some form of genetic alteration associated with their tumor which can be detected through genomic testing services offered by private laboratories.
This factor is projected to increase demand for treatment options over the forecast period, thereby driving growth during this period. However, a rise in incidence rates has led to an increase in research initiatives for discovering effective treatment options against non-seminoma types as well as seminoma tumors; this trend is expected to continue over the forecast period thus fueling growth during this period too.
Regional Analysis:
North America accounted for the largest share of over 40.0% in 2017, owing to the high incidence rate and prevalence of testicular cancer in U.S. In addition, rising adoption of innovative treatment techniques and increasing healthcare expenditure are other factors contributing to its largest market share. The region is expected to maintain its dominance throughout the forecast period due to continuous research & development activities by major pharmaceutical companies for developing novel drugs with improved efficacy and reduced toxicity compared to existing drugs.
Growth Factors:
- Increasing incidence of testicular cancer
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective drugs for treating testicular cancer
- Technological advancements in the field of oncology that are helping to develop new and more effective drugs for treating testicular cancer 5. Availability of government funding for research on testicular cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Testicular Cancer Drugs Market Research Report
By Type
Cisplatin, Etoposide, Ifosfamide, Paclitaxel, Vinblastine, Bleomycin, Dactinomycin
By Application
Seminomas, Non-Seminomas, Leydig Cell Cancer, Sertoli Cell Cancer
By Companies
Bristol-Myers Squibb, Pfizer, Ovation Pharmaceuticals, Teva Pharmaceutical, ZIOPHARM Oncology, Fresenius Kabi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
124
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Testicular Cancer Drugs Market Report Segments:
The global Testicular Cancer Drugs market is segmented on the basis of:
Types
Cisplatin, Etoposide, Ifosfamide, Paclitaxel, Vinblastine, Bleomycin, Dactinomycin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Seminomas, Non-Seminomas, Leydig Cell Cancer, Sertoli Cell Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Pfizer
- Ovation Pharmaceuticals
- Teva Pharmaceutical
- ZIOPHARM Oncology
- Fresenius Kabi
Highlights of The Testicular Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cisplatin
- Etoposide
- Ifosfamide
- Paclitaxel
- Vinblastine
- Bleomycin
- Dactinomycin
- By Application:
- Seminomas
- Non-Seminomas
- Leydig Cell Cancer
- Sertoli Cell Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Testicular Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Testicular cancer drugs are medications that can be used to treat testicular cancer. These drugs can help to shrink or kill the tumor, and may also improve the patient's overall health.
Some of the major companies in the testicular cancer drugs market are Bristol-Myers Squibb, Pfizer, Ovation Pharmaceuticals, Teva Pharmaceutical, ZIOPHARM Oncology, Fresenius Kabi.
The testicular cancer drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Testicular Cancer Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Testicular Cancer Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Testicular Cancer Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Testicular Cancer Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Testicular Cancer Drugs Market Size & Forecast, 2018-2028
4.5.1 Testicular Cancer Drugs Market Size and Y-o-Y Growth
4.5.2 Testicular Cancer Drugs Market Absolute $ Opportunity
Chapter 5 Global Testicular Cancer Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Testicular Cancer Drugs Market Size Forecast by Type
5.2.1 Cisplatin
5.2.2 Etoposide
5.2.3 Ifosfamide
5.2.4 Paclitaxel
5.2.5 Vinblastine
5.2.6 Bleomycin
5.2.7 Dactinomycin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Testicular Cancer Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Testicular Cancer Drugs Market Size Forecast by Applications
6.2.1 Seminomas
6.2.2 Non-Seminomas
6.2.3 Leydig Cell Cancer
6.2.4 Sertoli Cell Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Testicular Cancer Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Testicular Cancer Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Testicular Cancer Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Testicular Cancer Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Testicular Cancer Drugs Market Size Forecast by Type
9.6.1 Cisplatin
9.6.2 Etoposide
9.6.3 Ifosfamide
9.6.4 Paclitaxel
9.6.5 Vinblastine
9.6.6 Bleomycin
9.6.7 Dactinomycin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Testicular Cancer Drugs Market Size Forecast by Applications
9.10.1 Seminomas
9.10.2 Non-Seminomas
9.10.3 Leydig Cell Cancer
9.10.4 Sertoli Cell Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Testicular Cancer Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Testicular Cancer Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Testicular Cancer Drugs Market Size Forecast by Type
10.6.1 Cisplatin
10.6.2 Etoposide
10.6.3 Ifosfamide
10.6.4 Paclitaxel
10.6.5 Vinblastine
10.6.6 Bleomycin
10.6.7 Dactinomycin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Testicular Cancer Drugs Market Size Forecast by Applications
10.10.1 Seminomas
10.10.2 Non-Seminomas
10.10.3 Leydig Cell Cancer
10.10.4 Sertoli Cell Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Testicular Cancer Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Testicular Cancer Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Testicular Cancer Drugs Market Size Forecast by Type
11.6.1 Cisplatin
11.6.2 Etoposide
11.6.3 Ifosfamide
11.6.4 Paclitaxel
11.6.5 Vinblastine
11.6.6 Bleomycin
11.6.7 Dactinomycin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Testicular Cancer Drugs Market Size Forecast by Applications
11.10.1 Seminomas
11.10.2 Non-Seminomas
11.10.3 Leydig Cell Cancer
11.10.4 Sertoli Cell Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Testicular Cancer Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Testicular Cancer Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Testicular Cancer Drugs Market Size Forecast by Type
12.6.1 Cisplatin
12.6.2 Etoposide
12.6.3 Ifosfamide
12.6.4 Paclitaxel
12.6.5 Vinblastine
12.6.6 Bleomycin
12.6.7 Dactinomycin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Testicular Cancer Drugs Market Size Forecast by Applications
12.10.1 Seminomas
12.10.2 Non-Seminomas
12.10.3 Leydig Cell Cancer
12.10.4 Sertoli Cell Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Testicular Cancer Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Testicular Cancer Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Testicular Cancer Drugs Market Size Forecast by Type
13.6.1 Cisplatin
13.6.2 Etoposide
13.6.3 Ifosfamide
13.6.4 Paclitaxel
13.6.5 Vinblastine
13.6.6 Bleomycin
13.6.7 Dactinomycin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Testicular Cancer Drugs Market Size Forecast by Applications
13.10.1 Seminomas
13.10.2 Non-Seminomas
13.10.3 Leydig Cell Cancer
13.10.4 Sertoli Cell Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Testicular Cancer Drugs Market: Competitive Dashboard
14.2 Global Testicular Cancer Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb
14.3.2 Pfizer
14.3.3 Ovation Pharmaceuticals
14.3.4 Teva Pharmaceutical
14.3.5 ZIOPHARM Oncology
14.3.6 Fresenius Kabi
